The Urologic Oncology Program is the recipient of a $6.5 million Specialized Program of Research Excellence grant in prostate cancer, a George M. O'Brien Urology Research Center grant, a PO1 in prostate cancer metastasis to bone, and two T32 Urology Training Grants.
Evan Keller, DVM, Ph.D., co-director
The Urologic Oncology Program is one of the premier programs in its field nationally with expertise in urologic surgery, radiation oncology and medical oncology. The surgical team has special expertise in nerve-sparing prostatectomy for prostate cancer, neobladders for bladder cancer, retroperitoneal lymphadenectomy for testicular cancer and removal of kidney cancers invading the vena cava. In addition, the program's urologists have expertise in minimally invasive surgery (laparoscopic removal of tumors) and treatment of incontinence and impotence.
The U-M's radiation oncology group is among the most experienced in the world with three-dimensional conformal external radiation therapy for prostate cancer as well as pioneering seed implementation techniques. In addition, the program has developed an innovative therapeutic plan for effectively managing patients with advanced prostate cancer.
The Urologic Oncology Program is the recipient of a George M. O'Brien Urology Research Center grant, a PO1 in prostate cancer metastasis to bone, and two T32 Urology Training Grants. Active laboratory programs include work in the areas of prostate cancer genetics, gene discovery, metastasis, biomarker discovery, therapeutic development, and prostate and bladder cell biology. Recently, research has expanded broadly into specific evaluation of quality-of-life outcomes analyses for localized and metastatic bladder and prostate cancers. Clinical trials involving gene therapy, chemotherapy, immunotherapy and targeted agents are available for prostate, bladder and renal-cell cancers.
In addition, Urologic Oncology Program investigators participate in the Prostate Cancer Foundation's Clinical Research Consortium. The consortium ensures that leading cancer centers maintain a robust infrastructure for conducting prostate cancer clinical trials. The U-M Rogel Cancer Center is one of eight leading prostate cancer programs that form the consortium. Together, these institutions collaborate to rapidly and efficiently develop promising prostate cancer therapies. To date, Prostate Cancer Foundation has provided more than $17 million to this effort. More information on this and other initiatives can be found on their www.prostatecancerfoundation.org.